Somewhere between a podcast ad and a Instagram post from a wellness influencer, you’ve probably encountered the pitch: one blood draw, screening for more than 50 types of cancer at once, with results in about two weeks. Galleri is the name most people know, but it’s no longer the only option — Exact Sciences launched Cancerguard in 2025, and Guardant Health has a multi-cancer product moving through the FDA pipeline alongside its already-approved colorectal cancer blood test.
What’s harder to find is a clear-eyed answer to the question underneath the marketing: does any of this actually work, and for whom? That question got a real, if messy, answer in February 2026, when the largest randomized trial ever run on this technology — the NHS-Galleri trial, 140,000 people, three years of screening — reported results that were simultaneously a genuine positive finding and a missed primary endpoint. Most of the coverage that followed picked one half of that story and ran with it. This article tries to hold both halves at once, with citations to the primary sources.
Key takeaways
- The NHS-Galleri trial, the largest randomized test of a multi-cancer blood test to date, missed its primary combined-endpoint but found a real 14% overall reduction in stage IV cancer diagnoses across three annual rounds.
- No MCED test has been shown in a randomized trial to reduce cancer deaths — that data doesn’t exist yet for any product on the market, and won’t for years.
- Sensitivity for early-stage (stage I) cancer is the weakest part of every published dataset — as low as 12–20% for several cancer types — even as overall and late-stage sensitivity look much stronger.
- None of the multi-cancer products (Galleri, Cancerguard) are FDA-approved; they’re laboratory-developed tests. The one FDA-approved blood test in this space, Guardant Shield, is approved only for colorectal cancer — not multi-cancer detection.
- A new federal law creates a path for Medicare to eventually cover MCED tests, but not before 2028, and only for tests that get FDA approval first — which none currently have.
What a Multi-Cancer Early Detection Test Actually Does
When a tumor grows, some of its cells die and release fragments of DNA into the bloodstream — “cell-free DNA” (cfDNA). Cancer cells tend to carry distinctive patterns of chemical tags on that DNA, called methylation patterns, that differ from methylation patterns in healthy cells. MCED tests like Galleri sequence cell-free DNA from a blood draw, run it through a machine-learning classifier trained to recognize cancer-associated methylation patterns, and report back one of two results: “no cancer signal detected,” or “cancer signal detected,” paired with a prediction of which organ or tissue the signal most likely came from — called the cancer signal origin (CSO).
This is a fundamentally different approach from a single-cancer screening test like a mammogram or colonoscopy, which looks for one specific cancer in one specific location. An MCED test is scanning for a shared biological fingerprint across dozens of cancer types simultaneously, most of which — pancreatic, ovarian, esophageal, several head and neck cancers — currently have no recommended screening test of any kind for average-risk adults. That’s the real, legitimate appeal: it’s not competing with colonoscopy, it’s targeting the roughly 70% of cancer deaths that occur in cancers with no existing screening option, according to the American Cancer Society Cancer Action Network.
It’s also, mechanically, why these tests behave the way they do: tumor stage correlates with how much cfDNA a cancer sheds. A large, aggressive, late-stage tumor sheds a strong signal. A small, early-stage tumor sheds very little. That single fact explains almost everything interesting — and complicated — about how well these tests actually perform, covered below.
The 2026 Landscape: Galleri, Shield, and Cancerguard
Three products dominate the current market, and they are not interchangeable — mixing up what each one is actually approved and validated to do is the single most common source of confusion in coverage of this space.
| Test (maker) | What it actually does | Regulatory status | Cost |
|---|---|---|---|
| Galleri (GRAIL) | Screens for a shared cancer signal across 50+ cancer types plus tissue-of-origin prediction, in asymptomatic adults 50+ | Laboratory-developed test (CLIA/CAP); not FDA approved. GRAIL filed for FDA premarket approval in 2026. | $949 list, often $799 self-pay |
| Cancerguard (Exact Sciences) | Screens for a shared cancer signal across 50+ cancer types and subtypes | Laboratory-developed test (CLIA/CAP); not FDA cleared | Provider-dependent |
| Guardant Shield (colorectal) | Blood-based primary screening specifically for colorectal cancer in average-risk adults 45+ | FDA-approved (July 2024); added to updated 2026 ACS colorectal screening guidelines | Billed like other guideline-recommended CRC screening |
| Guardant Shield (multi-cancer) | Broader multi-cancer version, in development | FDA Breakthrough Device Designation only — not approved | Not yet commercially available |
That table is worth reading twice, because the Shield row is where a lot of marketing and casual reporting quietly blurs a line: Guardant’s colorectal cancer blood test is genuinely FDA-approved, evidence-backed, and now guideline-recommended — but that approval is for one cancer, using one dedicated test. Guardant’s actual multi-cancer product is a separate, earlier-stage pipeline asset with a Breakthrough Device Designation, which speeds up FDA review but is not an approval. Citing “FDA-approved” MCED technology by pointing at Shield’s colorectal approval is technically true and substantively misleading — exactly the kind of gap this article is trying to close.
Already up to date on your guideline-recommended screening? See exactly which established tests apply to your age and risk profile before considering anything experimental. Take the Fit Check →
What the Trials Actually Show
PATHFINDER and PATHFINDER 2: performance in the intended population
The original PATHFINDER study, led by researcher Deborah Schrag and published in The Lancet in 2023, tested an earlier prototype of the Galleri assay in 6,662 asymptomatic adults 50 and older. It reported 29% sensitivity at 99.1% specificity, with a 38% positive predictive value for that prototype version; a retrospective analysis modeling the updated, currently marketed version of the test estimated a PPV of 43% (95% CI 30.8–55.9%) at 99.5% specificity.
PATHFINDER 2, presented at the 2026 ASCO Annual Meeting with more than 35,000 participants, reported meaningfully improved numbers for the current commercial version of the test: 99.6% specificity (a false-positive rate under 0.4%), a 60.3% positive predictive value, and 92.5% accuracy in predicting the correct tissue of origin once a signal was detected. Adding Galleri to standard USPSTF-recommended screening increased overall cancer detection roughly seven-fold.
Those are genuinely strong specificity and PPV numbers for a screening test used at population scale — better, in fact, than several established screening tests’ real-world false-positive rates. The number that requires more scrutiny is sensitivity, covered in its own section below.
The NHS-Galleri trial: the real randomized answer, and the nuance the headlines missed
PATHFINDER measures how the test performs; it doesn’t tell you whether using it changes health outcomes. That question requires a randomized controlled trial — assign some people to get the test, others to standard care, and see what actually happens to their cancer diagnoses over time. The NHS-Galleri trial is that study: roughly 140,000 asymptomatic UK adults aged 50–77, randomized 2:1 to annual Galleri testing plus standard care, or standard care alone, followed across three annual screening rounds.
Reported at the 2026 ASCO Annual Meeting, the results were genuinely mixed, not a clean win or loss:
- Primary endpoint (missed): The trial was designed to detect a reduction in the combined number of stage III and stage IV cancer diagnoses within one year of each screening round. That combined endpoint did not reach statistical significance.
- Stage IV reduction (a real, positive secondary finding): Stage IV diagnoses among the 12 prespecified cancers fell 9%, 22%, and 26% across the first, second, and third annual rounds respectively — a 14% overall reduction.
- More early-stage detection: Stage I–II diagnoses of the deadliest cancers rose 16% in the intervention group.
- Fewer emergency diagnoses: Cancer diagnosed through emergency hospital presentation — a marker strongly associated with worse outcomes — fell 25% in the intervention arm.
- Four-fold increase in overall cancer detection when Galleri was added to standard NHS screening.
Why did the primary endpoint fail despite those secondary results? GRAIL’s own explanation, echoed by outside researchers, is that the trial saw a higher-than-anticipated rate of stage III diagnoses during the study period — diluting a combined “stage III+IV” metric that was mathematically dependent on both numbers moving together. Richard Neal, the trial’s co-chief investigator, noted that if the trial had been designed and powered around stage IV reduction alone — the outcome it actually hit — the result would read as “a huge success.” That’s a real, defensible point. It’s also an after-the-fact reframing of a pre-registered endpoint that didn’t work out, and readers should weigh both facts, not just the more flattering one.
The honest summary: this is the first randomized evidence that an MCED test can shift cancer diagnoses toward earlier, less advanced stages and reduce emergency presentations — a real and meaningful signal. It is not yet evidence that the test reduces cancer deaths, which is the outcome that ultimately matters and the one no MCED trial has reported to date.
The Sensitivity Problem the Marketing Doesn’t Lead With
Every specificity and PPV number above describes what happens when the test is right. The flip side — how often it misses a cancer that’s actually there — tells a much less flattering story, and it follows directly from the biology described earlier: small, early-stage tumors shed less DNA, and less DNA is harder to detect.
Overall sensitivity across all cancer types in PATHFINDER 2 was 39.3%; for the 12 cancers responsible for roughly two-thirds of U.S. cancer deaths specifically, sensitivity was higher, at 69.8%. But those headline averages combine performance across every stage, and stage-by-stage published data makes the real pattern clear:
| Cancer type | Stage I sensitivity | Stage II | Stage III | Stage IV | Overall |
|---|---|---|---|---|---|
| Pancreatic | 61.9% | 60.0% | 85.7% | 95.9% | 83.7% |
| Esophageal | 12.5% | 64.7% | 94.7% | 100% | 85.0% |
Source: PATHFINDER 2 stage-specific data, GRAIL 2026.
Physician Jesse Pines, writing an independent analysis for Forbes, put the pattern in blunter terms: across cancer types generally, Galleri’s sensitivity for stage I disease was measured at 16.8%, compared with over 90% for stage IV. That’s not a minor caveat — stage I is precisely the stage where early detection is supposed to matter most, because it’s when a cancer is most likely to be curable with surgery alone. A test that is excellent at finding cancer once it has already reached stage III or IV, and comparatively weak at finding it at stage I, is still useful — the NHS-Galleri stage IV reduction proves that — but it’s a meaningfully different product than “catches cancer early,” which is the phrase doing most of the marketing work.
False Positives, and What Actually Happens After One
Specificity above 99% sounds close to perfect, and in absolute terms it is high. But specificity alone doesn’t tell you what a positive result actually means for the person holding it — that’s what positive predictive value (PPV) measures, and it depends heavily on how common the disease being screened for is in the population being tested.
In the original PATHFINDER study, PPV for the prototype assay was 38%, meaning close to 6 in 10 positive results did not turn out to be cancer. PATHFINDER 2, testing the improved commercial assay in a larger sample, reported a much better PPV of 60.3% — a real, substantive improvement, though it still means roughly 4 in 10 positive results are false alarms. In the real-world NHS-Galleri population, PPV came in at 52% overall (58% in the first screening round).
A false positive isn’t a neutral event. It triggers what researchers call a diagnostic workup, guided by the test’s predicted tissue of origin — usually imaging, sometimes a biopsy or endoscopy. Pines’ reporting on the PATHFINDER cohort found this process took a median of around two months and, for some participants, considerably longer, with real costs, time off work, and anxiety attached regardless of the eventual outcome. It’s also worth knowing that in PATHFINDER, the majority of cancers ultimately diagnosed among participants — an estimated 71% — were caught by standard screening or symptoms, not by the Galleri test itself, a useful reminder that an MCED test is additive to, not a replacement for, existing screening.
This is a genuinely different risk profile from whole-body MRI screening, where most incidental findings are indolent, harmless abnormalities picked up because the scan is looking at everything. Because MCED tests are biologically weighted toward detecting cancers that are actively shedding DNA, the false-positive/overdiagnosis dynamic is somewhat less severe than with imaging — but it is not zero, and “less overdiagnosis-prone than an MRI” is a different claim than “accurate.”
Is It FDA Approved? Will Insurance Actually Cover It?
This is where a lot of current confusion sits, and it got more complicated, not less, in early 2026.
Regulatory status: As of mid-2026, neither Galleri nor Cancerguard is FDA-approved or FDA-cleared. Both are laboratory-developed tests (LDTs), regulated under CLIA and accredited by the College of American Pathologists — a different, less stringent regulatory pathway than FDA device approval. GRAIL submitted a premarket approval application to the FDA in 2026, but no decision has been announced. Guardant Shield’s colorectal-specific test is the exception: it received full FDA approval in July 2024 based on the 23,000-person ECLIPSE study (83% sensitivity for colorectal cancer, 90% specificity for advanced neoplasia), and was added to the American Cancer Society’s updated 2026 colorectal cancer screening guidelines. Guardant’s broader multi-cancer product remains in earlier-stage development with Breakthrough Device Designation only.
Medicare: On February 3, 2026, President Trump signed the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 842 / S. 339) into law as part of the FY2026 federal appropriations package, after bipartisan sponsorship from Reps. Jodey Arrington and Terri Sewell. The law is a real milestone, but it’s frequently misreported as “Medicare now covers Galleri.” What it actually does: it authorizes Medicare to cover MCED tests starting in 2028, and only for tests that have first received full FDA approval and that CMS separately determines are appropriate to cover. No MCED test currently satisfies that bar. Coverage is not retroactive, immediate, or automatic.
Private insurance and out-of-pocket cost: Most private insurance plans do not currently cover Galleri, Cancerguard, or Shield’s multi-cancer product; they are typically paid out of pocket. Galleri’s list price is $949, often discounted to around $799 through participating providers. Shield’s colorectal-specific test, by contrast, is billed through standard colorectal cancer screening pathways given its FDA approval and guideline inclusion — a meaningfully different financial and regulatory position than the multi-cancer products.
USPSTF: The U.S. Preventive Services Task Force, the body responsible for most official screening grades in the United States, has not evaluated or issued any recommendation for MCED tests as of mid-2026. Every “Grade A/B/C” reference you may see attached to Galleri or Cancerguard in marketing is not an official USPSTF grade — because none exists yet.
Who Should Actually Consider One
Putting the trial data, the sensitivity limitations, and the regulatory picture together, a reasonably evidence-based way to think about candidacy looks like this:
- A stronger case: Adults 50 and older who are current on all guideline-recommended screening (colonoscopy or equivalent, mammography, low-dose CT if a heavy smoking history applies, cervical screening if applicable) and who understand and accept the real chance of a false positive, in exchange for a shot at catching a cancer type — pancreatic, ovarian, several others — that has no dedicated screening test today.
- A weaker case: Adults under 50 with no elevated risk factors, where the underlying cancer prevalence in the population is lower, which mathematically drags down positive predictive value — a positive result in this group is proportionally more likely to be a false alarm than in an older population, even with an unchanged specificity.
- Not a substitute, in any case: No MCED test is validated or approved to replace colonoscopy, mammography, low-dose CT lung screening, or cervical cancer screening. Skipping an established, evidence-backed screening test in favor of an MCED test would trade a proven mortality benefit for an unproven one.
- A genuinely reasonable no: Choosing to wait — for FDA approval, for Medicare’s 2028 coverage pathway to mature, or for the NHS-Galleri and REACH (a U.S. Medicare-eligible trial specifically targeting stage IV reduction as its primary endpoint) trials to report longer follow-up — is not an unreasonable or uninformed choice for most people. It’s the more conservative reading of where the evidence actually stands right now.
How to Evaluate an MCED Test Before You Pay for One
- Ask for the specific sensitivity number by stage, not just the overall average — the gap between stage I and stage IV sensitivity is the single most important number that most marketing leaves out.
- Ask what the confirmed diagnostic workup process looks like after a positive, including who coordinates it, how long it typically takes, and what it costs beyond the initial test.
- Confirm the test’s regulatory status directly — laboratory-developed test versus FDA-approved is a real, substantive distinction, not a technicality.
- Don’t let it replace anything on your guideline-recommended screening schedule — treat it strictly as additive.
- Ask what happens with a negative result — a “no signal detected” result reduces but does not eliminate cancer risk, given sensitivity limitations, and shouldn’t be read as a clean bill of health.
The Bottom Line
Multi-cancer early detection blood tests are neither the breakthrough the marketing implies nor the false promise their harshest critics claim. The NHS-Galleri trial is real, randomized evidence that this technology can shift cancer diagnoses toward earlier stages and reduce emergency presentations — a genuine step forward for a category of medicine that, until recently, had almost no randomized data at all. It is also honest to say the trial’s primary endpoint didn’t hit, that early-stage sensitivity remains the weakest part of the technology by design, that no MCED test has FDA approval, and that “Medicare will cover this” is a 2028 possibility tied to conditions that haven’t yet been met — not a 2026 reality.
If you’re considering one of these tests, the useful question isn’t “does it work?” — it clearly does something, and the data on what and how well keeps getting better. The useful question is whether you’re the kind of candidate (screening-current, risk-aware, financially and emotionally prepared for a roughly 40–48% chance a positive result is a false alarm) for whom that “something” is currently worth $949 and the possibility of a stressful, months-long diagnostic workup for nothing. For a lot of people, the honest answer is: not yet, but worth revisiting once the FDA decision, longer trial follow-up, and the 2028 Medicare pathway all come into clearer focus.
Before considering an experimental blood test, make sure you're current on the screening that already has decades of proof behind it. Answer a few quick, non-identifying questions and get personalized eligibility guidance across all 6 categories ScanGlean covers. Take the Fit Check →
Frequently Asked Questions
What is a multi-cancer early detection (MCED) test?
An MCED test is a blood test that looks for a shared molecular signal — usually DNA methylation patterns on cell-free DNA shed by tumors — that can appear across many cancer types at once, and predicts which organ the signal is coming from. Galleri (GRAIL), Cancerguard (Exact Sciences), and Guardant Shield’s multi-cancer product are the best-known examples. None are approved to replace colonoscopy, mammography, or other established, guideline-recommended cancer screening.
Does the Galleri test actually reduce cancer deaths?
No randomized trial has shown this yet. The NHS-Galleri trial, the largest and most rigorous test of this question so far, missed its primary endpoint (a combined reduction in stage III and IV cancer diagnoses). It did find a real secondary benefit — a 14% overall reduction in stage IV diagnoses across three annual screening rounds — but stage IV reduction and mortality reduction are related, not identical, and no trial has yet reported on cancer deaths.
How accurate is the Galleri test?
In GRAIL’s 2026 PATHFINDER 2 study of over 35,000 people, Galleri had 99.6% specificity, a 60.3% positive predictive value, and 92.5% accuracy at identifying which organ a true signal came from. But sensitivity varies enormously by cancer stage: overall sensitivity across all cancer types was 39.3%, and for stage I disease specifically — the stage most doctors want to catch — published stage-by-stage data put sensitivity in the range of 12–20% for several cancer types.
Is the Galleri test FDA approved?
No. As of mid-2026, Galleri and Exact Sciences’ Cancerguard are both laboratory-developed tests regulated under CLIA/CAP, not FDA-approved or FDA-cleared devices. GRAIL filed for FDA premarket approval in 2026, but a decision has not been issued. The one FDA-approved blood-based test in this space, Guardant Shield, is approved specifically for colorectal cancer screening — a single-cancer indication, not the broader multi-cancer product.
Will Medicare or insurance cover an MCED test like Galleri?
Not yet, and not automatically. The Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, signed into law February 3, 2026, creates a pathway for Medicare to cover MCED tests — but only starting in 2028, only for tests that have received FDA approval, and only if CMS separately determines coverage is appropriate. No MCED test currently meets that bar. Most private insurance does not cover Galleri today; it is typically an out-of-pocket test.
Who should consider getting a multi-cancer blood test?
The strongest case is for adults 50 and older who have already completed their guideline-recommended screening (colonoscopy, mammogram, low-dose CT if eligible, Pap/HPV testing) and want an additional layer of detection for cancers that currently have no screening test at all, understanding the real chance of a false positive. It is not a substitute for those established screenings, and the evidence is weakest for younger, average-risk adults, where a positive result is more likely to be wrong than right.
What happens if my MCED test comes back positive?
A positive “cancer signal detected” result triggers a diagnostic workup guided by the test’s predicted tissue of origin — typically imaging, and often a biopsy — to confirm or rule out cancer. In GRAIL’s own PATHFINDER study, roughly 6 in 10 positive results led to a confirmed cancer diagnosis and the rest did not, and the confirmatory workup for a true positive took a median of about two months, longer for some cases. Ask your provider in advance what the follow-up pathway and its costs look like before testing.
This article is for general educational and informational purposes only. It is not medical advice, and it is not a substitute for diagnosis, treatment, or guidance from a licensed physician or other qualified healthcare provider. Always consult a clinician before making decisions about cancer screening or your health.
Sources
- GRAIL. GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting, 2026.
- GRAIL. GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting, 2026.
- Schrag D, Beer TM, McDonnell CH, et al. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study. The Lancet, 2023;402(10409):1251–1260.
- Pines J. Is The Galleri Cancer Test Worth It? A Doctor Explains. Forbes, 2026.
- Patient Care Online. NHS-Galleri Data Show Fewer Stage IV Cancers, but Primary Endpoint Missed, 2026.
- Drug Discovery News. What the NHS-Galleri trial really tells us about multi-cancer early detection, 2026.
- MedTech Dive. Grail files for FDA approval of multi-cancer early detection test, 2026.
- U.S. Food and Drug Administration. Shield – P230009 device approval, 2024.
- Guardant Health. Shield Blood Test Approved by FDA as a Primary Screening Option for Colorectal Cancer, 2024.
- Patient Care Online. Guardant Health’s Shield Multicancer Detection Blood Test Granted FDA Breakthrough Device Designation, 2026.
- Exact Sciences. Exact Sciences Launches Cancerguard, First-of-Its-Kind Multi-Cancer Early Detection Blood Test, 2025.
- 119th United States Congress. H.R.842 – Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act, 2025–2026.
- AZBio. Long Awaited Legislation on Multi Cancer Early Detection Tests for Medicare Beneficiaries Becomes Law, 2026.
- Hoffman RM, Fedewa SA, Smith RA, et al. Multicancer early detection testing: Guidance for primary care discussions with patients. Cancer, 2025.
- American Cancer Society Cancer Action Network. Emergent Science: Multi-Cancer Early Detection Tests.
- American Cancer Society. Multi-cancer Detection (MCD) Tests.
- Galleri. How Much Does the Galleri Test for Cancer Screening Cost?
- Galleri. Galleri Test Sensitivity & Specificity, for Healthcare Providers